{
    "clinical_study": {
        "@rank": "151497", 
        "acronym": "THORIDAL", 
        "arm_group": {
            "arm_group_label": "Thioridazine", 
            "arm_group_type": "Experimental", 
            "description": "Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study)."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I trial investigating the safety of using thioridazine in addition to\n      cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia."
        }, 
        "brief_title": "Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of AML according to the WHO Classification1\n\n          -  AML is refractory or relapsed (requiring at least 5% leukemic blasts in the bone\n             marrow, regardless of the presence of other features such as new or recurrent\n             dysplastic changes or extra medullary disease) according to the following\n             definitions:\n\n               -  Relapsed (defined as \u2265 5% leukemic blasts in the bone marrow) after three months\n                  from receiving up to two prior induction regimens.\n\n               -  Refractory (defined as \u2265 5% leukemic blasts in the bone marrow) to not more than\n                  one prior induction regimen (defined as failure to achieve a CR or CRi following\n                  induction therapy).\n\n          -  55 years of age or older.\n\n        Exclusion Criteria:\n\n          -  Receiving any other systemic anti-leukemic therapy (standard or investigational).\n\n          -  Having received more than two prior chemotherapy lines for AML.\n             Induction/consolidation therapy and bone marrow transplant are each considered a line\n             of therapy.\n\n          -  Having received previous AML therapy within four weeks of the first dose of study\n             drug, with the exception of hydroxyurea.\n\n          -  Clinical evidence suggestive of CNS involvement with leukemia unless a lumbar\n             puncture confirms the absence of leukemic blasts in the CSF.\n\n          -  Acute promyelocytic leukemia.\n\n          -  An ECOG performance status of 3 or more.\n\n          -  Inadequate renal function (i.e., estimated GFR < 60 mL/min/1.73m2).\n\n          -  Inadequate hepatic function (i.e., serum bilirubin > 1.5\u00d7ULN; AST, ALT and alkaline\n             phosphatase > 2.5\u00d7ULN).\n\n          -  Presence of acute or chronic GVHD.\n\n          -  Presence of a systemic fungal, bacterial, viral or other infection not controlled\n             (defined as exhibiting ongoing signs/symptoms related to the infection and without\n             improvement, despite appropriate antibiotics or other treatment).\n\n          -  Having any other severe concurrent disease, or have a history of serious organ\n             dysfunction or disease involving the heart, kidney, liver or other organ system that\n             may place the patient at undue risk to undergo induction therapy.\n\n          -  Diagnosed with a condition that can prolong the QT interval (e.g., long QT syndrome)\n             or have a QTc interval \u2265 470ms if male, or \u2265 480ms if female.\n\n          -  Left ventricular ejection fraction less than 45%.\n\n          -  History of uncontrolled cardiac arrhythmia.\n\n          -  Known severe hypotensive or hypertensive heart disease.\n\n          -  Prior malignancy, unless the patient has been disease-free for at least five years\n             following curative intent therapy, with the following exceptions: Patients with\n             treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial\n             neoplasia, regardless of the disease-free duration, if definitive treatment for the\n             condition has been completed; or patients with organ-confined prostate cancer with no\n             evidence of recurrent or progressive disease based on prostate-specific antigen (PSA)\n             values if hormonal therapy has been initiated or a radical prostatectomy has been\n             performed.\n\n          -  Known HIV positivity.\n\n          -  Known pregnancy or lactating female.\n\n          -  Presence of a psychiatric disorder that would interfere with consent, study\n             participation, or follow-up.\n\n          -  Unable to provide informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096289", 
            "org_study_id": "OCOG-2013-THORIDAL"
        }, 
        "intervention": {
            "arm_group_label": "Thioridazine", 
            "intervention_name": "Thioridazine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Thioridazine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Relapsed Acute Myeloid Leukemia", 
            "Refractory Acute Myeloid Leukemia", 
            "Thioridazine", 
            "Phase I", 
            "Clinical Trial"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "foleyr@hhsc.ca", 
                "last_name": "Ronan Foley, MD", 
                "phone": "905-527-4322", 
                "phone_ext": "42074"
            }, 
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8V 1C3"
                }, 
                "name": "Juravinski Hospital & Cancer Centre"
            }, 
            "investigator": {
                "last_name": "Ronan Foley, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease", 
        "overall_contact": {
            "email": "bcochra@mcmaster.ca", 
            "last_name": "Brandy Cochrane, MSc", 
            "phone": "905-527-2299", 
            "phone_ext": "42607"
        }, 
        "overall_official": [
            {
                "affiliation": "Ontario Clinical Oncology Group, McMaster University", 
                "last_name": "Mark N Levine, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hamilton Health Sciences, McMaster University", 
                "last_name": "Ronan Foley, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Both acute and late toxicities will be determined according to NCI-CTCAE version 4.03", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 36 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096289"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Bone marrow and peripheral blood samples obtained from patients treated with thioridazine and cytarabine will be analyzed in four separate assays.", 
                "measure": "Assessment of Functional Leukemia Stem Cells", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 days"
            }, 
            {
                "description": "Pharmacokinetic modeling will be performed to estimate values for individual C min levels.", 
                "measure": "Pharmacokinetic Analysis of Thioridazine Serum Trough Levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 days"
            }, 
            {
                "description": "Tumor responses are categorized as either a complete remission, a complete remission with incomplete count recovery, a partial remission, a treatment failure, or as not evaluable", 
                "measure": "Assessment of Objective Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 days"
            }, 
            {
                "description": "Cytochrome P450 2D6 genotype will be determined to examine genetic contribution to thioridazine Cmin levels.", 
                "measure": "Pharmacogenetic Analysis of Thioridazine Serum Trough Levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 days"
            }
        ], 
        "source": "Ontario Clinical Oncology Group (OCOG)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hamilton Health Sciences Corporation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Juravinski Cancer Centre Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ontario Clinical Oncology Group (OCOG)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}